On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
The new online Learning Center with new content can still be found under the “Training” folder on ...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...